Deinococcus grandis host vector system

By removing endogenous plasmids and constructing shuttle vectors with diverse replication initiation regions, the method stabilizes plasmid maintenance and expression in Deinococcus grandis, overcoming the challenges of homologous recombination and vector limitations, thereby enhancing its bioremediation capabilities.

WO2024247295A1PCT designated stage expired Publication Date: 2024-12-05TOYO UNIV EDUCATIONAL FOUND
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2023/034784
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-31
Filing Date
2023-09-25
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Deinococcus grandis host cells pose challenges in stably introducing and maintaining expression plasmids due to their high DNA repair ability, leading to frequent homologous recombination and instability of multiple plasmids, and the limited repertoire of plasmid vectors available, making it difficult to transform and express foreign genes effectively for bioremediation applications.

Method used

A method involving the removal of endogenous plasmids pDEGR-3 and pDEGR-PL from Deinococcus grandis, followed by the construction of shuttle vector plasmids with different replication initiation regions from E. coli and Deinococcus radiodurans, allowing for the stable maintenance and expression of multiple plasmids, thereby minimizing homologous recombination and enabling the introduction of foreign genes for bioremediation.

Benefits of technology

This approach allows for the stable introduction and expression of multiple plasmids in Deinococcus grandis, enhancing its bioremediation capabilities by reducing homologous recombination and expanding the repertoire of usable plasmid vectors, facilitating the expression of genes for radioactive substance removal and other bioremediation applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 000051
    Figure 000051
  • Figure 000052
    Figure 000052
  • Figure 000053
    Figure 000053
Patent Text Reader

Abstract

[Problem] To provide a Deinococcus grandis host vector system capable of stably introducing and maintaining an expression plasmid in Deinococcus grandis. [Solution] The present invention provides a host vector system comprising: a Deinococcus grandis host cell modified by removing mainly endogenous plasmid pDEGR-3 of Deinococcus grandis or endogenous plasmid pDEGR-3 and endogenous plasmid of 91 or 291 bp; a shuttle vector plasmid comprising a replication initiation region of the endogenous plasmid pDEGR-3 of Deinococcus grandis; and a shuttle vector plasmid comprising a replication initiation region of a plasmid derived from a Deinococcus radiodurans Sark strain.
Need to check novelty before this filing date? Find Prior Art

Description

Deinococcus grandis host-vector system

[0001] The present invention relates to a method for transforming Deinococcus grandis, particularly to the use of Deinococcus grandis modified to introduce a foreign plasmid, as well as to a shuttle vector plasmid between Deinococcus grandis and Escherichia coli, an expression plasmid for a target gene using the shuttle vector plasmid, and a transformant incorporating the expression plasmid.

[0002] The radiation resistance of living organisms varies greatly depending on the species. To date, a group of bacteria with extremely high radiation resistance has been known, and these are called radioresistant bacteria. If genes capable of removing persistent or harmful substances or genes involved in the intracellular uptake of elements could be introduced into these radioresistant bacteria by genetic engineering techniques, or if their expression could be enhanced, it would be possible to remove persistent or harmful substances contained in radionuclide-contaminated waste, or to remove radionuclides from radioactively contaminated soil or rivers. Therefore, genetic transformation of radioresistant bacteria is extremely useful as a bioremediation technology for removing radioactive materials.

[0003] Among radioresistant bacteria, the bacteria that have been most extensively studied and for which genetic engineering techniques can be used are the Deinococcus bacteria. It is known that the radiation resistance of Deinococcus bacteria is approximately 100 times greater than that of Escherichia coli and approximately 1000 times greater than that of human cells. Among Deinococcus bacteria, the one that has been most frequently studied is Deinococcus radiodurans. Deinococcus radiodurans is a mesophilic bacterium with an optimum growth temperature of 30°C, and typically takes the form of a tetrastreptococcus. This bacterium is polyploid (4-10 copies of the genome per cell) and is known to have a high natural transformation potential. The strong radiation resistance exhibited by Deinococcus bacteria is thought to be primarily due to their extremely high DNA repair ability.

[0004] To date, examples of bioremediation techniques using Deinococcus radiodurans include one in which the toluene dioxygenase gene derived from Pseudomonas putida was expressed on the chromosome of Deinococcus radiodurans to convert persistent toluene into a more easily degradable substance (Non-Patent Document 1); one in which the divalent mercury ion reduction gene derived from Escherichia coli was expressed on the chromosome of Deinococcus radiodurans to reduce divalent mercury ions to less toxic volatile metallic mercury (Non-Patent Document 2); and one in which the non-specific acid phosphatase gene derived from Salmonella enterica typhi or the alkaline phosphatase gene derived from Sphingomonas bacteria was expressed on a plasmid using Deinococcus radiodurans as a host to precipitate uranium from a uranyl nitrate solution (Non-Patent Documents 3, 4, and 5). There are also examples in which an endoglucanase gene derived from Bacillus pumilus was expressed on a plasmid using Deinococcus radiodurans as a host, with the aim of contributing to the bioremediation of cellulosic waste in radioactive environments (Non-Patent Document 6); an example in which a synthetic gene encoding a phytochelatin analog or a metallothionein gene derived from a bacterium of the genus Synechococcus was expressed on a plasmid using Deinococcus radiodurans as a host, thereby improving the cadmium accumulation ability (Non-Patent Document 7); and an example in which a nickel / cobalt transporter gene derived from Rhodopseudomonas palustris or Novosphingobium aromaticivorans was expressed on a plasmid using Deinococcus radiodurans as a host, thereby improving the efficiency of removing radioactive cobalt from radioactively contaminated water (Non-Patent Document 8). In addition, there is an example in which a divalent mercury ion reduction gene derived from Escherichia coli was expressed on a plasmid using Deinococcus diothermalis as a host, and divalent mercury ions were reduced to less toxic volatile metallic mercury (Non-Patent Document 9).

[0005] In relation to genetic engineering techniques for bacteria of the genus Deinococcus, to date, plasmid vectors for expressing foreign genes using Deinococcus radiodurans or Deinococcus geothermalis as a host are limited to the Deinococcus radiodurans-Escherichia coli shuttle vector pI3, which was developed using a replicon of the Deinococcus radiodurans Sark strain-derived plasmid pUE10 and an Escherichia coli vector, and its derivative plasmids (Non-Patent Documents 10 and 11), and there have been no examples of expressing foreign genes using plasmid vectors with replicons other than the pI3 system.

[0006] Furthermore, in the course of functional analysis of DNA repair genes in Deinococcus bacteria, it has been reported that pI3-based plasmids can also replicate in D. deserti (Non-Patent Document 12), but to date, no research examples of bioremediation using D. deserti have been reported. Furthermore, plasmid vectors that can replicate in D. deserti are limited to pI3-based plasmids, and there have been no examples of transforming D. deserti with a plasmid vector having a replicon other than pI3.

[0007] Furthermore, the plasmid vector pZT15 and its derivative plasmids have been developed for expressing genes using Deinococcus grandis as a host (see Patent Document 1 and Non-Patent Document 13), and there is an example of creating a complemented strain by expressing the rodZ gene of Deinococcus grandis on a plasmid using a rodZ gene-deficient strain of Deinococcus grandis as a host (Non-Patent Document 14), but to date no research examples of bioremediation using Deinococcus grandis have been reported. Furthermore, there has been no example demonstrating that plasmids with replicons other than pZT15-based plasmids can replicate in Deinococcus grandis.

[0008] The genome of the standard strain of Deinococcus grandis (ATCC 43672) has been reported to have a 3,241,502 bp chromosome, a 389,567 bp plasmid (pDEGR-1), a 373,915 bp plasmid (pDEGR-2), a 91,291 bp plasmid (since none of the prior art documents mention a specific name for this plasmid, it will be referred to as "pDEGR-PL" in this specification), and an 8,055 bp plasmid (pDEGR-3), and the genome sequence information for these has been made public in DNA databases (Non-Patent Documents 15 and 16). To date, there have been no examples of vectorization of these Deinococcus grandis plasmids.

[0009] As mentioned above, Deinococcus bacteria are radioresistant and have an extremely high DNA repair ability. Therefore, if DNA regions with the same base sequence exist on multiple plasmids, homologous recombination repair proteins will frequently occur between the plasmids, making it extremely difficult to stably maintain multiple plasmids within the bacteria.

[0010] Another problem is that the size of a DNA fragment that can be stably integrated into a plasmid vector is generally considered to be up to about 10 kbp. In other words, expression plasmids incorporating large DNA fragments are thought to be unstable in host cells. Therefore, particularly when transforming host cells with multiple genes, it is desirable to use multiple types of plasmid vectors to reduce the total size of the genes integrated into a single plasmid. However, the repertoire of known plasmid vectors that can be used in Deinococcus grandis is not very large. In addition, as mentioned above, when using multiple types of plasmid vectors, homologous recombination reactions between them must also be suppressed.

[0011] Patent No. 3845697 specification

[0012] Lang et al. , Nature Biotechnol. , 16:929-933, 1998 Brim et al. , Nature Biotechnol. , 18:85-90, 2000 Appukuttan et al. , Appl. Environ. Microbiol. , 72:7873-7878, 2006 Appukuttan et al. , J. Biotechnol. , 154:285-290, 2011 Kulkarni et al. , J. Hazard. Mater. , 262:853-861, 2013 Telang et al. , 3 Biotech, 4:57-65, 2014 Chaturvedi and Archana, Biometals, 27: 471-482, 2014 Gogada et al. , Appl. Microbiol. Biotechnol. , 99:9203-9213, 2015 Brim et al. , Appl. Environ. Microbiol. , 69:4575-4582, 2003 Masters and Minton, Plasmid, 28:258-261, 1992 Meima and Lidstrom, Appl. Environ. Microbiol. , 66:3856-3867, 2000 Dulermo et al. , Mol. Microbiol. , 74:194-208, 2009 Satoh et al. , Plasmid, 62:1-9, 2009 Nishino et al. , Microbiology, 164:1361-1371, 2018 Satoh et al. , Genome Announce. , 4: e01631-15, 2016 Shibai et al. , Microbiol. Resour. Announcement. , 8: e01226-19, 2019

[0013] Therefore, an objective of the present invention is to provide a Deinococcus grandis host-vector system that can stably introduce and maintain an expression plasmid in Deinococcus grandis.

[0014] Another additional object of the present invention is to provide a Deinococcus grandis host-vector system that can use multiple types of plasmid vectors.

[0015] To solve the above problems, the present inventors conceived that by using as a host cell a modified Deinococcus grandis strain (ATCC 43672) in which the endogenous plasmid had been removed (as used herein, the terms "removal" and "deletion" have the same meaning when referring to a plasmid), it would be possible to prevent homologous recombination between the endogenous plasmid and an introduced expression plasmid. Therefore, the inventors attempted to remove pDEGR-3 as the endogenous plasmid, but were unable to do so using typical plasmid removal methods used by those skilled in the art (see, for example, Trevors, FEMS Microbiol. Rev., 32:149-157, 1986). Faced with such technical difficulties, the inventors attempted to remove pDEGR-3 by devising a special method described below, and succeeded in removing the endogenous plasmid.

[0016] The present inventors also removed an endogenous plasmid with a size of 91,291 bp present in the standard strain of Deinococcus grandis. The endogenous plasmid pDEGR-PL could be removed relatively more easily than pDEGR-3.

[0017] Furthermore, the present inventors have constructed a shuttle vector plasmid (as used herein, the terms "shuttle vector plasmid," "shuttle vector," "shuttle plasmid," and "plasmid vector" have the same meaning unless otherwise specified) that can be used in the Deinococcus grandis host cells modified as described above. Specifically, because the endogenous plasmid pDEGR-3 has been removed from the modified Deinococcus grandis host cells of the present invention, a shuttle vector plasmid containing the replication origin region of pDEGR-3 was constructed. The present inventors have then demonstrated that an expression plasmid based on this shuttle vector plasmid can be stably maintained in the modified Deinococcus grandis host cells of the present invention.

[0018] Furthermore, the present inventors have constructed another shuttle vector plasmid that can be used in the modified Deinococcus grandis host cells of the present invention. Specifically, a shuttle vector plasmid was constructed that contains the pUE10 rep region, which is a replicon derived from the Deinococcus radiodurans Sark strain plasmid pUE10, and a replication origin that is different from the replication origin of the E. coli-derived plasmid used in the shuttle vector plasmid containing the replication origin of pDEGR-3. In this way, the possibility of homologous recombination between the shuttle vector plasmids was minimized, and both expression plasmids based on these two shuttle vector plasmids were stably maintained in the modified Deinococcus grandis host cells of the present invention. Thus, according to a first aspect of the present invention, the following method is provided.<1> A method for transforming Deinococcus grandis, comprising the following steps: (1) removing from Deinococcus grandis the endogenous plasmid pDEGR-3 or the endogenous plasmid pDEGR-3 and the 91,291 bp endogenous plasmid pDEGR-PL to obtain a genetically modified microbial host cell; (2) constructing the following shuttle vector plasmids: a. a shuttle vector plasmid comprising the replication origin of pDEGR-3 removed in (1) above and the replication origin of an E. coli-derived plasmid; b. a shuttle vector plasmid comprising the replication origin of a plasmid derived from the Deinococcus radiodurans Sark strain and the replication origin of an E. coli-derived plasmid; or c. the shuttle vector plasmid of a above a and the shuttle vector plasmid of b above, wherein the two shuttle vector plasmids comprise replication origins of different E. coli-derived plasmids; (3) constructing the following expression plasmids: a'. (b') an expression plasmid in which one or more genes of interest to be expressed in a host cell have been inserted into the cloning site of the shuttle vector plasmid constructed in (b) above; or (c') an expression plasmid in which one or more genes of interest to be expressed in a host cell have been inserted into the cloning site of each shuttle vector plasmid constructed in (c) above, provided that the genes of interest inserted into each shuttle vector plasmid are different from each other; (4) introducing the expression plasmid constructed in (3) above into E. coli and amplifying it; and (5) transforming the host cell of (1) above with the expression plasmid amplified in (4) above.

[0019] The first aspect of the present invention also includes the following preferred embodiments. <2> The method of <1> above, wherein the replication origin region of pDEGR-3 contained in the shuttle vector plasmid of (a) corresponds to pDEGR-3 rep, which is a replicon derived from pDEGR-3. <3> The method of <1> above, wherein the replication origin region of the plasmid derived from the Deinococcus radiodurans Sark strain contained in the shuttle vector plasmid of (b) corresponds to pUE10 rep, which is a replicon derived from the Deinococcus radiodurans Sark strain plasmid pUE10. <4> The method of <1> above, wherein the shuttle vector plasmid of (2) further contains an antibiotic resistance gene as a screening marker.

[0020] Furthermore, pZT15 and its derivative plasmids are known as plasmid vectors that can be used for gene expression in Deinococcus grandis host cells (see Patent Document 1 and Non-Patent Document 13). The present inventors have demonstrated that these known plasmid vectors can stably coexist in the modified Deinococcus grandis host cells of the present invention without interfering with either of the two shuttle vector plasmids of the present invention. Therefore, the first aspect of the present invention also includes the following embodiments. <5> The method of any of <1> to <4> above, further comprising: (3') constructing an expression plasmid by inserting one or more genes of interest to be expressed in a host cell into a cloning site of a shuttle vector plasmid selected from the Deinococcus / E. coli shuttle vector pZT15 series plasmids, wherein the genes of interest are different from any of the genes of interest a' to c' above and the shuttle vector plasmid contains a replication origin of an E. coli-derived plasmid different from the replication origin of an E. coli-derived plasmid contained in a' to c' above; (4') introducing the expression plasmid constructed in (3') above into E. coli and amplifying it; and (5') transforming the host cell of (1) above with the expression plasmid amplified in (4'). <6> The method of <5> above, wherein the shuttle vector plasmid in (3') further contains an antibiotic resistance gene as a screening marker.

[0021] Furthermore, according to a second aspect of the present invention, there are provided the following shuttle vector plasmids suitable for use in the method according to the first aspect of the present invention. <7> A shuttle vector plasmid comprising the pDEGR-3 rep region, which is a replicon derived from Deinococcus grandis endogenous plasmid pDEGR-3, the p15A on region, which is a replicon derived from E. coli vector pACYC184, and an antibiotic resistance gene as a screening marker. <8> The shuttle vector plasmid of <7> above, wherein the antibiotic resistance gene is the aad gene, which is a streptomycin resistance gene derived from E. coli vector pGBM5. <9> A shuttle vector plasmid comprising the pUE10 rep region, which is a replicon derived from Deinococcus radiodurans Sark strain plasmid pUE10, the pSC101 on rep region, which is a replicon derived from E. coli vector pSC101, and a second antibiotic resistance gene as a screening marker. <10> The shuttle vector plasmid according to <9> above, wherein the second antibiotic resistance gene is a cat gene, which is a chloramphenicol resistance gene derived from the Escherichia coli vector pcDNA3.1CAT.

[0022] Furthermore, according to a third aspect of the present invention, there are provided the following expression plasmids based on the shuttle vector plasmid according to the second aspect of the present invention: <11> An expression plasmid in which one or more genes of interest for expression in a host cell are inserted into the cloning site of the shuttle vector plasmid of <7> or <8> above. <12> An expression plasmid in which one or more genes of interest for expression in a host cell are inserted into the cloning site of the shuttle vector plasmid of <9> or <10> above.

[0023] Furthermore, according to a fourth aspect of the present invention, there are provided the following transformants obtainable by the method according to the first aspect of the present invention: <13> A transformant in which the expression plasmid of <11> above has been introduced into a genetically modified microbial host cell of <1> above. <14> A transformant in which the expression plasmid of <12> above has been introduced into a genetically modified microbial host cell of <1> above. <15> A transformant in which the expression plasmid of <11> above and the expression plasmid of <12> above, each having a different gene of interest inserted therein, have been introduced into a genetically modified microbial host cell of <1> above, thereby enabling expression of different genes on the two types of plasmids. <16> A transformant obtained by further introducing a second expression plasmid into the transformant of <13> above, wherein the second expression plasmid contains one or more second genes of interest inserted into the cloning site of a shuttle vector plasmid selected from the Deinococcus / E. coli shuttle vector pZT15 series, and the replication origin of the E. coli-derived plasmid contained in the shuttle vector plasmid is not the p15A ori region, thereby enabling expression of different genes on two types of plasmids. <17> A transformant obtained by further introducing a second expression plasmid into the transformant of <14> above, wherein the second expression plasmid contains one or more second genes of interest inserted into the cloning site of a shuttle vector plasmid selected from the Deinococcus / E. coli shuttle vector pZT15 series, and the replication origin of the E. coli-derived plasmid contained in the shuttle vector plasmid is not the pSC101 ori rep region, thereby enabling expression of different genes on two types of plasmids.<18> A transformant according to <15> above, wherein a third expression plasmid is further introduced, the third expression plasmid comprising one or more third genes of interest inserted into a cloning site of a shuttle vector plasmid selected from the Deinococcus / Escherichia coli shuttle vector pZT15 series plasmids, and the replication origin region of an E. coli-derived plasmid contained in the shuttle vector plasmid is neither the p15A ori region nor the pSC101 ori rep region, thereby enabling expression of three different genes on the plasmids.

[0024] According to the present invention, a Deinococcus grandis host-vector system is provided that can stably introduce and maintain an expression plasmid in Deinococcus grandis. As an additional effect of the present invention, a Deinococcus grandis host-vector system is provided that can use multiple types of plasmid vectors.

[0025] Figure 1 shows an agarose gel electrophoresis image of a plasmid extracted from a colony of the Deinococcus grandis standard strain (ATCC 43672). Lanes 1 to 10 show extracts derived from colonies obtained after incubation at 40°C, and lane 11 shows extracts derived from a control that was not incubated at 40°C. The 8,055 bp plasmid pDEGR-3 was observed in all lanes 1 to 11. Figure 2 shows the results of agarose gel electrophoresis confirming the presence or absence of PCR amplification products derived from the DEIGR_400031 gene, DEIGR_400086 gene, and DEIGR_400127 gene present in the endogenous plasmid pDEGR-PL of Deinococcus grandis ATCC 43672. In the plasmid map of pDEGR-PL in this figure, A indicates the PCR amplification site of the DEIGR_400031 gene region, B indicates the PCR amplification site of the DEIGR_400086 gene region, and C indicates the PCR amplification site of the DEIGR_400127 gene region. Furthermore, in the agarose electrophoresis image in this figure, M indicates a commercially available linear DNA molecular size marker. Lanes 1 to 5 show PCR reactions performed using genomic DNA prepared from Deinococcus grandis ATCC 43672 that had not been cultured at 40°C as a control, and lanes 6 to 10 show PCR reactions performed using as a template a genome derived from a colony obtained after culture at 40°C. Also, lanes 1 and 6 are PCR products of the glutamine synthetase gene region (723 bp) present in the chromosome, lanes 2 and 7 are PCR products of the DEIGR_400031 gene region (623 bp) present in the plasmid pDEGR-PL, lanes 3 and 8 are PCR products of the DEIGR_400086 gene region (659 bp) present in the plasmid pDEGR-PL, lanes 4 and 9 are PCR products of the DEIGR_400127 gene region (687 bp) present in the plasmid pDEGR-PL, lanes 5 and 10 are PCR products of the DEIGR_500007 gene region (750 bp) present in the plasmid pDEGR-3. From these results, it was shown that the plasmid pDEGR-PL is deleted in Deinococcus grandis after culture at 40 ° C., but the plasmid pDEGR-3 is retained.FIG. 3 is an agarose electrophoresis image showing the results of deleting the plasmid pDEGR-3 from Deinococcus grandis (TY1 strain), which was shown to have deleted the plasmid pDEGR-PL but retained the plasmid pDEGR-3. Lane 1 shows a plasmid extracted from the Deinococcus grandis TY1 strain, lane 2 shows a plasmid extracted from the Deinococcus grandis TY1Nluc strain, lanes 3 and 4 show extracts derived from colonies obtained from bacterial broth cultured at 40°C in TGY medium containing 5 ng / μl of novobiocin, and lanes 5 and 6 show extracts derived from colonies obtained from bacterial broth cultured at 40°C in TGY medium containing 5 ng / μl of rifampicin. In lane 1, the 8,055 bp plasmid pDEGR-3 was observed, and in lane 2, the 8,961 bp plasmid pDEGR-3Δ8LA containing Nluc and a streptomycin resistance gene (aad) instead of the DEIGR_500008 gene was observed, whereas no plasmids were observed in lanes 3 to 6. These results indicated that Deinococcus grandis (TY3 strain) lacking the pDEGR-3 plasmid present in the TY1 strain was obtained. Figure 4 shows a map of the shuttle vector pGRC5 containing the pDEGR replicon of Deinococcus grandis ATCC 43672. In Figure 4, pDEGR-3 rep represents the replicon of the 8,055 bp plasmid of Deinococcus grandis ATCC 43672, p15A ori represents the replicon derived from the E. coli vector pACYC184, katA-p represents the catalase gene promoter of Deinococcus radiodurans, and aad represents the streptomycin resistance gene derived from the E. coli vector pGBM5. Figure 5 shows a map of the shuttle vector pRADN8 containing the replicon derived from the Deinococcus radiodurans Sark strain plasmid pUE10.In Figure 5, pUE10 rep represents the replicon derived from the Deinococcus radiodurans Sark strain plasmid pUE10, pSC101 ori rep represents the replicon derived from the E. coli vector pSC101, katA-p represents the catalase gene promoter of Deinococcus radiodurans, and cat represents the chloramphenicol resistance gene derived from the E. coli vector pcDNA3.1CAT. Figure 6 shows a map of the shuttle vector pZT29H constructed based on pZT29, a plasmid in the Deinococcus / E. coli shuttle vector pZT15 series. In Figure 6, pUE30 rep represents the replicon derived from the plasmid pUE30 of Deinococcus radiopugnans ATCC19172, pUC19 ori represents the replicon derived from the E. coli vector pUC19, katA-p represents the catalase gene promoter of Deinococcus radiodurans, and hyg represents the hygromycin resistance gene derived from the E. coli vector pDR2. Figure 7 shows an agarose electrophoresis image showing the retention of the shuttle vectors pGRC5, pRADN8, and pZT29H in transformants of Deinococcus grandis strain TY3. Lane 1 represents the plasmid pDERG-3 (8,055 bp) extracted from the Deinococcus grandis strain TY1, and lane 2 represents the extract derived from the Deinococcus grandis strain TY3. Lane 3 shows a transformant into which pGRC5 (3,908 bp) was introduced, lane 4 shows a transformant into which pZT29H was introduced (bands are observed at the 4,601 bp position derived from the pZT29H monomer and the 9,202 bp position derived from the pZT29H dimer), and lane 5 shows a transformant into which pRADN8 was introduced (bands are observed at the 6,046 bp position derived from the pRAND8 monomer and the 12,092 bp position derived from the pRAND8 dimer).), lane 6 shows a transformant containing two plasmids, pGRC5 and pZT29H, lane 7 shows a transformant containing two plasmids, pZT29H and pRADN8, lane 8 shows a transformant containing two plasmids, pRADN8 and pGRC5, lane 9 shows a transformant containing three plasmids, pGRC5, pZT29H, and pRADN8, and lane M shows a commercially available supercoiled DNA size marker. The arrows indicate genomic DNA present in the plasmid extract. These results demonstrate that the plasmids pGRC5, pZT29H, and pRAND8 can coexist in the Deinococcus grandis TY3 strain. 8 shows agarose electrophoresis images confirming the size and state of the plasmids in transformants obtained by introducing the shrimp lobster luciferase gene expression plasmids pGRC5GN, pZT29HGN, and pRADN8GN into Deinococcus grandis TY3 strain. Lane M shows a commercially available supercoiled DNA size marker, lane 1 shows a transformant introduced with pGRC5GN (4,545 bp), lane 2 shows a transformant introduced with pZT29HGN (5,250 bp), and lane 3 shows a transformant introduced with pRADN8GN (6,683 bp). The arrows indicate genomic DNA present in the plasmid extract.

[0026] Deinococcus grandis Host Cells In the present invention, cells modified by removing (deleting) an endogenous plasmid from a wild-type strain of Deinococcus grandis are used as hosts for transformation. As used herein, the term "endogenous plasmid" refers to a plasmid present in a wild-type strain. As used herein, the term "wild-type strain" includes not only naturally occurring bacterial strains and bacterial strains isolated from nature, but also bacterial strains that have undergone any modification (whether genetic or non-genetic) other than the modification of the present invention. An example of a wild-type strain that can be used in the present invention is the standard strain of Deinococcus grandis (ATCC 43672). This strain is available from the American Type Culture Collection.

[0027] The genome of the standard strain of Deinococcus grandis (ATCC43672) has been reported to have a 3,241,502 bp chromosome and four plasmids: a 389,567 bp plasmid (pDEGR-1), a 373,915 bp plasmid (pDEGR-2), a 91,291 bp plasmid, and an 8,055 bp plasmid (pDEGR-3). These genome sequence information has been published in the DNA database (Non-Patent Document 15: Satoh et al., Genome Announcement, 4: e01631-15, 2016, and Non-Patent Document 16: Shibai et al., Microbiol.Resour.Announcement, 8: e01226-19, 2019). Since the 91,291 bp plasmid is not given a specific name in these literature or databases, this plasmid is referred to as "pDEGR-PL" in this specification. The sequence information of pDEGR-PL and pDEGR-3 is registered as <https: / / www.ncbi.nlm.nih.gov / nuccore / BCMS01000006> and <https: / / www.ncbi.nlm.nih.gov / nuccore / BCMS01000007>, respectively.

[0028] According to the present invention, the two plasmids pDEGR-3 or pDEGR-3 and pDEGR-PL are cured from a wild-type strain of Deinococcus grandis.

[0029] Various methods for deleting plasmids from microorganisms are known (see Trevors, FEMS Microbiol. Rev., 32:149-157, 1986). Plasmid pDEGR-PL can be deleted by such known methods. For example, as described in the Examples below, the plasmid can be deleted by repeatedly culturing the Deinococcus grandis ATCC 43672 strain at a permissive high temperature.

[0030] However, it was not easy to remove the other plasmid, pDEGR-3, and it could not be deleted by the same method as that used for the plasmid pDEGR-PL. Therefore, as described in the Examples below, the present inventors successfully produced a strain of Deinococcus grandis in which the plasmid pDEGR-3 had been deleted by applying a double selection pressure to the microorganism, i.e., by inserting a marker gene into the plasmid pDEGR-3 and then repeatedly culturing it at a high permissible temperature.

[0031] The strain (TY3 strain) in which the plasmid pDEGR-3 and plasmid pDEGR-PL of Deinococcus grandis ATCC 43672 produced as described above have been deleted was deposited on April 12, 2023, at the National Institute of Technology and Evaluation's Patent Microorganisms Depositary (NPMD) under the accession number NITE BP-03880, under the Budapest Treaty.

[0032] Shuttle Vector Plasmid As mentioned above, Deinococcus bacteria have extremely high DNA repair capabilities, so when DNA regions with the same base sequence are present on multiple plasmids, homologous recombination reactions between the plasmids occur frequently due to the action of homologous recombination repair proteins. For this reason, when Deinococcus bacteria are used as hosts, it is extremely difficult to stably maintain multiple plasmids within the bacteria. Therefore, the present invention also provides a shuttle vector plasmid that can be stably maintained in the Deinococcus grandis host cells of the present invention. Specifically, in order to avoid plasmid instability due to base sequence homology, the inventors constructed a shuttle vector plasmid in which the replication origins of three types of Escherichia coli-derived plasmids with different base sequences are linked to the replication origins of three types of Deinococcus-derived plasmids with different base sequences.

[0033] One shuttle vector plasmid according to the present invention contains the replication origin of the endogenous Deinococcus grandis plasmid pDEGR-3. That is, since the present invention uses host cells from which the plasmid pDEGR-3 has been removed from Deinococcus grandis, the replication origin of the plasmid pDEGR-3 can be advantageously utilized. Naturally, this shuttle vector plasmid can also be used in host cells from which the plasmids pDEGR-3 and pDEGR-PL have been removed from Deinococcus grandis. The replication origin of the endogenous Deinococcus grandis plasmid pDEGR-3 in the shuttle vector plasmid according to the present invention can be exemplified by the region corresponding to pDEGR-3 rep, which is a replicon derived from pDEGR-3.

[0034] The shuttle vector plasmid of the present invention also contains a replication origin region of an E. coli-derived plasmid. Such a replication origin region may include any replication origin sequence present in an E. coli-derived plasmid. Therefore, a specific example of the shuttle vector plasmid of the present invention is a shuttle plasmid containing a replicon (pDEGR-3 rep) derived from Deinococcus grandis ATCC 43672 plasmid pDEGR-3 and a replicon (p15A ori) derived from the E. coli vector pACYC184.

[0035] In one preferred embodiment of the present invention, an antibiotic resistance gene is added to the shuttle plasmid as a screening marker. This ensures the presence of the plasmid in the bacterial cells upon addition of an antibiotic to the culture medium, extraction and purification of the plasmid from the bacterial cells, and introduction of the plasmid into the bacterial cells by transformation. Non-limiting examples of such antibiotic resistance genes include streptomycin resistance genes, chloramphenicol resistance genes, hygromycin resistance genes, tetracycline resistance genes, ampicillin resistance genes, and puromycin resistance genes. Therefore, preferred specific examples of the shuttle vector plasmid of the present invention include shuttle plasmids having a replicon (pDEGR-3 rep) derived from Deinococcus grandis ATCC 43672 plasmid pDEGR-3, a replicon (p15A ori) derived from E. coli vector pACYC184, and a streptomycin resistance gene (aad) derived from E. coli plasmid pGBM5.

[0036] Another shuttle vector plasmid according to the present invention contains a replication origin of a plasmid derived from the Deinococcus radiodurans Sark strain. An example of the replication origin of a plasmid derived from the Deinococcus radiodurans Sark strain is the region corresponding to pUE10 rep, a replicon derived from the Deinococcus radiodurans Sark strain plasmid pUE10. The present inventors have experimentally confirmed that a shuttle vector plasmid having such a replication origin can also be stably maintained in the Deinococcus grandis host cells of the present invention. More notably, the present inventors have experimentally demonstrated that the shuttle vector plasmid can coexist with any of the other shuttle vectors of the present invention (i.e., vector plasmids having the replication origin of plasmid pDEGR-3 and / or plasmids of the Deinococcus / E. coli shuttle vector pZT15 series) in the Deinococcus grandis host cells of the present invention without interfering with each other. That is, although it is known that the replication origins of the three E. coli-derived plasmids used in the Examples herein can coexist in E. coli without interfering with each other, it was completely unknown whether the replication origins of the three Deinococcus-derived plasmids interfere with each other. Surprisingly, in the present invention, three shuttle vector plasmids each formed by linking the replication origins of three Deinococcus-derived plasmids with different nucleotide sequences were able to express foreign genes intracellularly in the Deinococcus grandis host cells of the present invention without interfering with each other.

[0037] The replication origin region of the E. coli-derived plasmid contained in another shuttle vector plasmid of the present invention may also contain any replication origin sequence present in an E. coli-derived plasmid. However, when more than one shuttle vector plasmid of the present invention is introduced into Deinococcus grandis of the present invention, the replication origin regions of the E. coli-derived plasmid contained in each shuttle vector plasmid should be different from each other. Therefore, a specific example of another shuttle vector plasmid of the present invention is a shuttle plasmid containing the pUE10 rep region, which is a replicon derived from the Deinococcus radiodurans Sark strain plasmid pUE10, and the pSC101 ori rep region, which is a replicon derived from the E. coli vector pSC101.

[0038] It is also preferable to add an antibiotic resistance gene as a screening marker to another shuttle vector plasmid of the present invention. However, when more than one shuttle vector plasmid of the present invention is introduced into Deinococcus grandis of the present invention, the antibiotic resistance genes contained in each shuttle vector plasmid should be different from each other. Therefore, specific examples of suitable another shuttle vector plasmid of the present invention include shuttle plasmids having a replicon derived from Deinococcus radiodurans Sark strain plasmid pUE10 (pUE10 rep), a replicon derived from E. coli vector pSC101 (pSC101 ori rep), and a chloramphenicol resistance gene (cat) derived from E. coli vector pcDNA3.1CAT.

[0039] In relation to the antibiotic resistance gene, each of the three shuttle vector plasmids described in the Examples of this specification (hereinafter referred to as the "three shuttle vectors") uses a different antibiotic resistance gene as its screening marker. However, it should be noted that the expression of each of these antibiotic resistance genes is controlled by the promoter (katA-p) of the catalase gene derived from Deinococcus radiodurans, located upstream of the gene. That is, this promoter region has the same nucleotide sequence in all three shuttle vectors. However, based on many years of research experience with Deinococcus bacteria, the inventors have found that homologous recombination does not occur in Deinococcus bacteria if the promoter region is less than 150 base pairs in size (unpublished work). Therefore, the inventors were able to empirically predict that the stability of the three shuttle vectors would not be affected by the nucleotide sequence homology provided by the catalase gene promoter, even when they coexist in the Deinococcus grandis host of the present invention. Furthermore, the present invention has confirmed that homologous recombination does not occur in Deinococcus bacteria if the size of the overlapping region between plasmids is less than 150 base pairs. However, if desired, different promoters can be used for each antibiotic resistance gene. It will be readily apparent to those skilled in the art that another shuttle vector plasmid according to the present invention, which contains the replication origin region of a plasmid derived from the Deinococcus radiodurans Sark strain, can also be used when a wild-type strain of Deinococcus grandis (e.g., ATCC 43672 strain) is used as the host.

[0040] Other shuttle vector plasmids that can be suitably used in the Deinococcus grandis host of the present invention are shuttle vector plasmids selected from the Deinococcus / Escherichia coli shuttle vector pZT15 series plasmids. In this specification, pZT15 series plasmids are defined as shuttle vector plasmids that use a pUE30 fragment involved in the replication of endogenous plasmid pUE30 derived from Deinococcus radiopugnans (D. radiopugnans) strain ATCC19172 as the origin of replication in Deinococcus bacteria and that also have the origin of replication of a plasmid derived from E. coli. Some pZT15 series plasmids are known and can be used in the present invention. Examples of pZT15-based plasmids include pZT15, pZT17, pZT23, pZT27, pZT29, and pZT90, which have been described in the literature (see Japanese Patent No. 3845697 (Patent Document 1) and Satoh et al., Plasmid, 62:1-9, 2009 (Non-Patent Document 13)). Any of these can be used as the Deinococcus / E. coli shuttle vector pZT15-based plasmid of the present invention. In addition, their derivatives, typically shuttle vectors having an E. coli replication origin different from the E. coli replication origin used in the shuttle vectors described in the literature and / or an antibiotic resistance gene different from the antibiotic resistance gene used in the shuttle vectors described in the literature, can also be used in the present invention. Therefore, the Deinococcus / E. coli shuttle vector pZT15 series plasmids of the present invention include shuttle vector plasmids having an E. coli replication origin different from the E. coli replication origin and / or an antibiotic resistance gene different from the antibiotic resistance gene contained in pZT15, pZT17, pZT23, pZT27, pZT29, and pZT90. It will be readily apparent to those skilled in the art that other shuttle vector plasmids of the present invention selected from the Deinococcus / E. coli shuttle vector pZT15 series plasmids can also be used when a wild-type strain of Deinococcus grandis (e.g., ATCC 43672 strain) is used as a host.

[0041] The shuttle vector plasmid of the present invention preferably has a multi-cloning site. The multi-cloning site may include restriction enzyme recognition sites such as EcoRV, HindIII, ClaI, SalI, XhoI, KpnI, BamHI, XbaI, SalI, PstI, SphI, HindIII, EcoRI, and SacI. The shuttle vector plasmid of the present invention having such a multi-cloning site can be prepared by methods well known to those skilled in the art.

[0042] Expression Plasmid The present invention uses an expression plasmid constructed by inserting one or more genes of interest into the cloning site of a shuttle vector plasmid according to the present invention. As used herein, the term "gene of interest" refers to a gene encoding a protein to be expressed. The gene of interest may be a gene derived from an organism different from the host microorganism, or may be a gene derived from a microorganism of the same strain, species, or genus as the host microorganism, and whose expression is desired to be enhanced in the host cell of the present invention.

[0043] The target gene can be inserted as an "expression cassette" into the cloning site of the shuttle vector plasmid of the present invention. As used herein, "expression cassette" refers to nucleotides comprising a nucleic acid sequence that regulates transcription and translation, operably linked to a nucleic acid to be expressed or a gene to be expressed. Typically, the expression cassette of the present invention comprises a promoter sequence 5' upstream from the coding sequence, a terminator sequence 3' downstream, and optionally further conventional regulatory elements operably linked thereto; in such a case, the nucleic acid to be expressed or the gene to be expressed is "expressibly introduced" into the host microorganism.

[0044] A promoter, whether constitutive or regulated, is defined as a DNA sequence that causes RNA polymerase to bind to DNA and initiate RNA synthesis. A strong promoter is a promoter that initiates mRNA synthesis at a high frequency and is suitable for use in the present invention. Non-limiting examples of promoters that can be used in the expression plasmids of the present invention include the promoter of the groES gene of Deinococcus radiodurans and the promoters of the DR1261, rpmB, and dnaK genes, which are known to induce high gene expression in Deinococcus radiodurans (see Chen et al., Appl. Environ. Microbiol., 85: e01356-19, 2019). Other promoters that can be suitably used in the expression plasmids of the present invention include promoters that are located upstream of the pprA, ddrA, ddrB, gyrB, and other genes and have nearby operator sequences known as radiation-desiccation response motifs (see Tanaka et al., Genetics, 168:21-33, 2004). By placing a gene to be expressed downstream of these promoters, gene expression can be induced and regulated by adding ultraviolet light, mitomycin C, methylmethanesulfonate, ethidium bromide, or the like to the culture medium of the transformant (see Narasimha and Basu, J. Biosci., 46:10, 2021).

[0045] Multiple genes can also be inserted into the shuttle vector plasmid of the present invention. Dual expression vectors have already been developed in which high-expression promoters are located at two positions, allowing separate genes to be inserted downstream of each promoter (see Novy et al., in Novations, 15:2-6, 2002 and Murakami et al., PLOS ONE, 16:e0258553, 2021). By locating high-expression promoters at two or more positions in each shuttle vector plasmid of the present invention, it becomes possible to express a larger group of genes.

[0046] Amplification and Transformation The expression plasmid of the present invention can be amplified in E. coli. Any E. coli strain used in conventional molecular biology research can be used as a host cell for amplifying the expression plasmid of the present invention. For example, E. coli hosts include, but are not limited to, strains derived from E. coli K12 or B strains.

[0047] To introduce the expression plasmid of the present invention into host microbial cells, conventional transfection methods such as co-precipitation and electroporation can be used. Examples of these methods are described in "Current Protocols in Molecular Biology," F. Ausubel et al., Publ. Wiley Interscience, New York, 1997, or Sambrook et al., "Molecular Cloning: A Laboratory Manual, Second Edition," Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

[0048] E. coli into which the expression plasmid of the present invention has been introduced as described above is cultured under conditions suitable for its growth. Suitable medium compositions, culture conditions, and culture times for transformants derived from various host microbial cells are known to those skilled in the art. The medium may be a natural, semi-synthetic, or synthetic medium containing one or more carbon sources, nitrogen sources, inorganic salts, vitamins, and, optionally, trace elements or vitamins and other trace components. The medium may also contain an antibiotic corresponding to the screening marker (antibiotic resistance gene) contained in the expression plasmid to be amplified. Cultivation should be continued while maintaining appropriate temperature, oxygen concentration, pH, and other parameters. The appropriate culture temperature for E. coli is typically between 25°C and 37°C. E. coli culture is preferably performed with shaking or stirring to ensure an appropriate oxygen concentration during growth. These culture conditions are easily determined by those skilled in the art. The expression plasmid of the present invention can be recovered by selecting a strain carrying the desired expression plasmid from among transformant strains exhibiting resistance to the antibiotic added to the medium.

[0049] The recovered expression plasmid can be used to transform the modified Deinococcus grandis host cells of the present invention. Conventional transfection methods, such as the co-precipitation method and electroporation described above, can also be used to introduce the expression plasmid of the present invention into Deinococcus grandis host cells.

[0050]

[0033] Examples of applications of the Deinococcus grandis transformant of the present invention include bioremediation related to the removal of radioactive materials by utilizing the radiation resistance of the host. In particular, the present invention makes it possible to express multiple bioremediation-related exogenous genes in Deinococcus grandis. For example, it is now possible to express multiple bioremediation-related foreign genes in Deinococcus grandis (e.g., the toluene dioxygenase gene from Pseudomonas putida, the divalent mercury ion reduction gene from Escherichia coli, the nonspecific acid phosphatase gene from Salmonella enterica typhi, the alkaline phosphatase gene from Sphingomonas bacteria, the endoglucanase gene from Bacillus pumilus, the metallothionein gene from Synechococcus bacteria, and the nickel / cobalt transporter genes from Rhodopseudomonas palustris or Novosphingobium aromaticivorans), thereby utilizing the host's radiation resistance to realize bioremediation related to the removal of radioactive materials.

[0051] Applications of the Deinococcus grandis transformant according to the present invention do not necessarily have to be related to the radioresistance characteristic of Deinococcus bacteria. Therefore, other examples of applications of the Deinococcus grandis transformant according to the present invention may include the application of Deinococcus bacteria to other bioremediation methods and the use of the bacteria as other industrially useful genetic resources. To date, Deinococcus bacteria have been reported to have the ability to produce deinoxanthin, an antioxidant with a high active oxygen scavenging effect (Lemee et al., Tetrahydron, 53:919-926, 1997), to decompose polycyclic aromatic hydrocarbons, which are urban air pollutants (Waight et al., J. Gen. Microbiol., 53:265-272, 2007), to decompose ethyl acetate, a marine pollutant (Kongpol et al., FEMS Microbiol. Lett., 286:227-235, 2008), to produce polyamines that are effective in extending healthy lifespan (Hamana et al., Journal of Extremophile Microbiology, 8:59-68, 2009), and to decompose dibutyl phthalate, an endocrine disruptor (Liao et al., al., Chemosphere, 78:342-346, 2010), the ability to produce quorum-quenching enzymes that can be used to prevent food spoilage, bacterial infection, and bioremediation (Keliah et al., Open Microbiol. J., 5:1-3, 2011), the ability to degrade malachite green, which is prohibited for use in aquatic animals (Lv et al., Bioresour. Technol., 144:275-280, 2013), the ability to degrade 17β-estradiol, an endocrine disruptor (Xiong et al., 3 Biotech, 8:433, 2018), and the ability to alleviate heavy metal toxicity in rice (Dai et al. al., Environ. Pollut., 284:117127, 2021), and the ability to reduce arsenic (V) ions, which are highly harmful to the human body, thereby reducing their toxicity (Zhang et al., Environ. Pollut., 312:120040, 2022).

[0052] The production of the antioxidant deinoxanthin mentioned above, which has a high active oxygen scavenging effect; the decomposition of polycyclic aromatic hydrocarbons, which are urban air pollutants; the decomposition of ethyl acetate, which is a marine pollutant; the production of polyamines, which are effective in extending healthy lifespan; the decomposition of dibutyl phthalate, which is an endocrine disruptor; the production of quorum quenching enzymes, which can be used to prevent food spoilage, bacterial infection, and bioremediation; the decomposition of malachite green, which is prohibited for use in aquatic animals; the decomposition of 17β-estradiol, which is an endocrine disruptor; and the decomposition of heavy metal toxins in rice. By introducing into the expression plasmid of the present invention a group of genes derived from Deinococcus bacteria that are associated with the alleviation of toxicity and the reduction of arsenic (V) ions, which are highly harmful to the human body, into the expression plasmid of the present invention and transforming Deinococcus grandis, it is possible to efficiently produce a host with enhanced abilities to decompose harmful substances and produce useful substances. This is expected to contribute to the fields of bioremediation as well as the production of anti-aging cosmetics and health foods (see, for example, International Publication No. WO2022 / 050559).

[0053] In particular, since the expression of useful traits such as the ability to degrade harmful substances and the ability to produce useful substances often involves multiple types of genes, by introducing a group of genes derived from Deinococcus bacteria involved in the expression of these useful traits into the expression plasmid of the present invention and transforming Deinococcus grandis, it is possible to efficiently produce a host with enhanced ability to degrade harmful substances and the ability to produce useful substances.

[0054] The present invention is further illustrated by the following examples, which are not intended to limit the scope of the present invention.

[0055] Example 1: Preparation of Deinococcus grandis Plasmid-Deleted Strain TY1 Deinococcus grandis ATCC 43672 obtained from the American Type Culture Collection was cultured in TGY medium (0.5% bactotryptone, 0.3% yeast extract, 0.1% glucose) at 40°C for 48 hours with shaking. The resulting bacterial solution was inoculated onto TGY agar medium (0.5% bactotryptone, 0.3% yeast extract, 0.1% glucose, 1.5% bacto agar) and cultured statically at 30°C for 48 hours. Ten colonies grown on the TGY agar medium were randomly picked, inoculated into 1 ml of TGY medium, and cultured at 30°C for 24 hours. Glycerol was added to the culture to prepare a glycerol stock, which was then stored at -80°C.

[0056] A small amount of the glycerol stock was inoculated into 4 ml of TGYM medium (TGY medium + 70 μM manganese chloride), and the cells were cultured at 30°C for 24 hours, from which the plasmid was extracted using a standard method (see Non-Patent Document 13). As a control, a plasmid was also extracted in the same manner from Deinococcus grandis ATCC 43672 that had been cultured at 30°C but not at 40°C. Analysis by agarose gel electrophoresis was performed to confirm whether the plasmid pDEGR-3 was retained in the cells.

[0057] The agarose electrophoresis image of the extracted plasmid is shown in Figure 1. In Figure 1, lanes 1 to 10 show extracts derived from colonies obtained after incubation at 40°C, and lane 11 shows extracts derived from a control that was not incubated at 40°C. The 8,055 bp plasmid pDEGR-3 was observed in all lanes 1 to 11.

[0058] A glycerol stock derived from a colony obtained after culturing at 40°C was inoculated into 4 ml of TGY medium, and genomic DNA was extracted from the cells after culturing at 30°C for 24 hours using a FastDNA SPIN Kit (manufactured by MP Biomedicals). As a control, genomic DNA was also extracted in the same manner from Deinococcus grandis ATCC 43672 that had not been cultured at 40°C. PCR was performed using the extracted genomic DNA as a template and Tks Gflex DNA polymerase (Takara Bio Inc.), and the presence or absence of PCR amplification products derived from the glutamine synthetase gene present in the chromosome of Deinococcus grandis ATCC43672, the DEIGR_400031 gene, DEIGR_400086 gene, DEIGR_400127 gene present in the plasmid pDEGR-PL, and the DEIGR_500007 gene present in the plasmid pDEGR-3 was confirmed by agarose gel electrophoresis.

[0059] The primers used for PCR amplification are as follows (SEQ ID NOs: 1 to 10). The primers were designed with reference to the following DNA databases: Deinococcus grandis genome sequence (https: / / www.ncbi.nlm.nih.gov / nuccore / BCMS01000001), (https: / / www.ncbi.nlm.nih.gov / nuccore / BCMS01000006), and (https: / / www.ncbi.nlm.nih.gov / nuccore / BCMS01000007).

[0060] Forward primer for glutamine synthetase gene fragment (DEIGR_102181vF: SEQ ID NO: 1) CAGCAGCCCGGCGTTCATCATGCGT

[0061] Reverse primer for glutamine synthetase gene fragment (DEIGR_102181vR: SEQ ID NO: 2) ATGCGCAGCAGGTCCTGGTGCTCGT

[0062] Forward primer for DEIGR_400031 gene fragment (DEIGR_400031vF: SEQ ID NO: 3) CTCAACCTCAAGCAGGAAGCCG

[0063] Reverse primer for DEIGR_400031 gene fragment (DEIGR_400031vR: SEQ ID NO: 4) TTGTTCCCGTCGCCGTTCTTC

[0064] Forward primer for DEIGR_400086 gene fragment (DEIGR_400086vF: SEQ ID NO: 5) ATGACGGGGCTGACCGGCGATGCTCT

[0065] Reverse primer for DEIGR_400086 gene fragment (DEIGR_400086vR: SEQ ID NO: 6) AGTTGCGCCGGCTCTCACGTGGACTT

[0066] Forward primer for DEIGR_400127 gene fragment (DEIGR_400127vF: SEQ ID NO: 7) CTCACGCAGCCGAACGCGGAGGTCAA

[0067] Reverse primer for DEIGR_400127 gene fragment (DEIGR_400127vR: SEQ ID NO: 8) CGTGGCCTGCATCAGTGCCCGCAGT

[0068] Forward primer for DEIGR_500007 gene fragment (DEIGR_500008vF: SEQ ID NO: 9) TAGGCTGTCCGCGTGTCCGC

[0069] Reverse primer for DEIGR_500007 gene fragment (DEIGR_500008vR: SEQ ID NO: 10) CTAGTGCCCCAGCTCCGGGAC

[0070] The results are shown in Figure 2. In the plasmid map of pDEGR-PL in this figure, A indicates the PCR amplification site of the DEIGR_400031 gene region, B indicates the PCR amplification site of the DEIGR_400086 gene region, and C indicates the PCR amplification site of the DEIGR_400127 gene region. In the agarose electrophoresis image in Figure 2, M indicates a commercially available linear DNA molecular size marker. Lanes 1 to 5 show the results of a PCR reaction performed using genomic DNA prepared from Deinococcus grandis ATCC 43672 that had not been cultured at 40°C as a control, and lanes 6 to 10 show the results of a PCR reaction performed using as a template the genome derived from a colony obtained after culture at 40°C. Lanes 1 and 6 show the PCR product of the glutamine synthetase gene region (723 bp) present in the chromosome, lanes 2 and 7 show the PCR product of the DEIGR_400031 gene region (623 bp) present in plasmid pDEGR-PL, lanes 3 and 8 show the PCR product of the DEIGR_400086 gene region (659 bp) present in plasmid pDEGR-PL, lanes 4 and 9 show the PCR product of the DEIGR_400127 gene region (687 bp) present in plasmid pDEGR-PL, and lanes 5 and 10 show the PCR product of the DEIGR_500007 gene region (750 bp) present in plasmid pDEGR-3. The PCR products in lanes 2 to 4, which were confirmed to be amplified in the control, were not observed at all in lanes 7 to 9. These results indicated that the plasmid pDEGR-PL was deleted in Deinococcus grandis after culture at 40°C, but the plasmid pDEGR-3 was retained, and this strain was designated Deinococcus grandis strain TY1.

[0071] Example 2: Preparation of Deinococcus grandis plasmid-deficient strain TY3 In order to facilitate screening of Deinococcus grandis strain TY1 for strains lacking the plasmid pDEGR-3, a Deinococcus grandis strain was prepared in which the DEIGR_500008 gene present in pDEGR-3 was replaced with the luciferase gene derived from Deinococcus grandis and a gene for resistance to the antibiotic streptomycin. The preparation method is as follows.

[0072] First, a 263 bp promoter fragment of the DNA damage response repressor DdrO gene was PCR-amplified using the genomic DNA of Deinococcus grandis ATCC 43672 as a template. Next, a 564 bp luciferase gene fragment from Deinococcus grandis was PCR-amplified using the pNL1.1[Nluc] vector (Promega) as a template. The 263 bp PCR fragment was treated with the restriction enzymes KpnI and NcoI, and the 564 bp PCR fragment was treated with the restriction enzymes NcoI and XhoI. This was then ligated into the KpnI and XhoI sites of the streptomycin resistance gene delivery plasmid pKatAAD2 (see Satoh et al., Microbiology, 152:3217-3226, 2006) to construct the plasmid pRNKAAD.

[0073] Next, using the genomic DNA of Deinococcus grandis ATCC43672 as a template, 769 bp upstream of the DEIGR_500008 gene and 770 bp downstream of the DEIGR_500008 gene were PCR-amplified fragments were mixed and treated with the restriction enzymes EcoRI, KpnI, PstI, and HindIII. Also, using the plasmid pRNKAAD as a template, a 3,025 bp fragment containing Nluc and the streptomycin resistance gene (aad) was PCR-amplified using primers that amplify the pUC19 insert and treated with KpnI and PstI. These three restriction enzyme-treated fragments were ligated into the EcoRI and HindIII sites of the plasmid pUC19 to construct the plasmid pΔ500008LA. Furthermore, a fragment was PCR-amplified using the plasmid pΔ500008LA as a template with primers that amplify the pUC19 insert, and the fragment was used to transform Deinococcus grandis ATCC43672 by the method described in Non-Patent Document 13. A streptomycin-resistant colony was obtained and designated as strain TY1Nluc.

[0074] The primers used for PCR amplification are as follows (SEQ ID NOs: 11 to 20). The primers were designed with reference to the following DNA databases: Deinococcus grandis genome sequence (https: / / www.ncbi.nlm.nih.gov / nuccore / BCMS01000007), pNL1.1[Nluc] sequence (https: / / www.ncbi.nlm.nih.gov / nuccore / JQ437370.1), and pUC19 sequence (https: / / www.ncbi.nlm.nih.gov / nuccore / 6691170). Restriction enzyme digestion sites are underlined.

[0075] Forward primer for the promoter region of the DNA damage response repressor DdrO gene (ddrO-RDRM5Kpn: SEQ ID NO: 11) ATCAGGTACCTCTGCTGTGGGCGAATCCTTCTTG

[0076] Reverse primer for the promoter region of the DNA damage response repressor DdrO gene (ddrO-RDRM3Nco: SEQ ID NO: 12) CGTACCATGGTTCACCTCCTCGGCTGCG

[0077] Forward primer for luciferase gene fragment derived from Pleurotus niger (Nluc-5Nco: SEQ ID NO: 13): GCCACCATGGTCTTCACACTCGAAGATTTCGTTGG

[0078] Reverse primer for luciferase gene fragment derived from Polytrichum nigra (Nluc-3Xho: SEQ ID NO: 14) GCTACTCGAGCGGCCGGCCGCCCC

[0079] Forward primer for the upstream region of the DEIGR_500008 gene (DEIGR_500008-Eco5F: SEQ ID NO: 15) ATGCGAATTCTAGGCTGTCCGCGTGTCCGC

[0080] Reverse primer for the upstream region of the DEIGR_500008 gene (DEIGR_500008-Kpn5R: SEQ ID NO: 16) CGATGGTACCTAGTGCCCCAGCTCCGGGAC

[0081] Forward primer for the downstream region of the DEIGR_500008 gene (DEIGR_500008-Pst3F: SEQ ID NO: 17) ATGCCTGCAGCCGCCTCAGATGACCTGCTGA

[0082] Reverse primer for the downstream region of the DEIGR_500008 gene (DEIGR_500008-Hin3R: SEQ ID NO: 18) CTACAAGCTTAGCCGCCAACAACACTCATTCC

[0083] Forward primer for amplifying the insert of pUC19 (pKat-FP: SEQ ID NO: 19) CGACGGCCAGTGAATTCGAGC

[0084] Primer for amplifying the insert of pUC19 Reverse primer (pKat-RP: SEQ ID NO: 20) CAGCTATGACCATGATTACGCCAAGC

[0085] In addition to culturing at high temperatures, methods using chemicals are known for deleting microbial plasmids (see Trevors, FEMS Microbiol. Rev., 32:149-157, 1986). Based on this, the TY1Nluc strain was cultured in TGY medium supplemented with 5 ng / μl novobiocin or 5 ng / μl rifampicin at 40°C for 48 hours with shaking, and the resulting bacterial solution was diluted 100-fold and inoculated into TGY medium supplemented with 5 ng / μl novobiocin or 5 ng / μl rifampicin, followed by shaking culture at 40°C for 72 hours. This culture was then plated on TGY agar medium and subjected to static culture at 30°C for 48 hours. Two colonies that were non-luciferase-producing and streptomycin-sensitive growing on TGY agar medium were picked, inoculated into 1 ml of TGY medium, and cultured for 24 hours at 30°C. Glycerol was added to the culture solution to prepare a glycerol stock, which was then stored at -80°C.

[0086] Plasmids were extracted from Deinococcus grandis by the same procedure as in Example 1, and whether the plasmids were retained in the cells was confirmed by agarose gel electrophoresis. The results are shown in FIG. In this figure, lane 1 shows a plasmid extracted from the Deinococcus grandis TY1 strain, lane 2 shows a plasmid extracted from the Deinococcus grandis TY1Nluc strain, lanes 3 and 4 show extracts derived from colonies obtained from bacterial broth cultured at 40°C in TGY medium containing 5 ng / μl of novobiocin, and lanes 5 and 6 show extracts derived from colonies obtained from bacterial broth cultured at 40°C in TGY medium containing 5 ng / μl of rifampicin. In lane 1, the 8,055 bp plasmid pDEGR-3 was observed, and in lane 2, the 8,961 bp plasmid pDEGR-3Δ8LA containing Nluc and a streptomycin resistance gene (aad) instead of the DEIGR_500008 gene was observed, whereas no plasmid was observed in lanes 3 to 6. These results indicated that the resulting Deinococcus grandis lacked the plasmid pDEGR-3 present in the TY1 strain, and this strain was designated Deinococcus grandis TY3.

[0087] Example 3: Construction of Deinococcus grandis-Escherichia coli shuttle vector pGRC5 A 933 bp fragment containing a replicon was PCR-amplified using the E. coli vector pACYC184 as a template and digested with the restriction enzymes SphI and KpnI. Additionally, the plasmid pKatAAD2, which can express the streptomycin resistance gene (aad) derived from the E. coli plasmid pGBM5 (obtained from the National Institute of Genetics) using the catalase gene promoter (katA-p) of Deinococcus radiodurans, was digested with SphI and KpnI to obtain a 981 bp DNA fragment. These DNA fragments were ligated to construct the plasmid pKatAAD2L.

[0088] Next, using the 8,055 bp plasmid pDEGR-3 from Deinococcus grandis ATCC 43672 as a template, a 2,022 bp fragment containing the replicon (pDEGR-3 rep) was PCR amplified and then treated with KpnI. This fragment was ligated into the KpnI site of the plasmid pKatAAD2L to construct the plasmid pGRC5. A map of the shuttle vector pGRC5 is shown in Figure 4. In Figure 4, pDEGR-3 rep represents the replicon of the 8,055 bp plasmid from Deinococcus grandis ATCC 43672, p15A ori represents the replicon derived from the E. coli vector pACYC184, katA-p represents the catalase gene promoter from Deinococcus radiodurans, and aad represents the streptomycin resistance gene derived from the E. coli vector pGBM5.

[0089] The primers used for PCR amplification are as follows (SEQ ID NOs: 21 to 24). The primers were designed with reference to the DNA database: - the base sequence of pACYC184 (https: / / www.ncbi.nlm.nih.gov / nuccore / X06403), and - the genome base sequence of Deinococcus grandis (https: / / www.ncbi.nlm.nih.gov / nuccore / BCMS01000007). The underlined fragments indicate restriction enzyme digestion sites.

[0090] Forward primer of the replicon derived from E. coli vector pACYC184 (p15A-FP_Sph: SEQ ID NO: 21) GACTGCATGCGCGCTAGCGGAGTGTATACTGG

[0091] Reverse primer of the replicon derived from E. coli vector pACYC184 (p15A-RP_Kpn: SEQ ID NO: 22) TGCAGGTACCACAACTTATATCGTATGGGGCTGAC

[0092] Forward primer of the replicon of the 8,055 bp plasmid pDEGR-3 of Deinococcus grandis ATCC 43672 (DEGR3F1Kpn: SEQ ID NO: 23) AGCTGGTACCACTTTGACGATCTTGGGGGAATGAG

[0093] Reverse primer for the replicon of the 8,055 bp plasmid pDEGR-3 of Deinococcus grandis ATCC 43672 (DEGR3R1Kpn: SEQ ID NO: 24) ACGTGGTACCATGATGACCACCCGGCTCATG

[0094] Example 4: Construction of Deinococcus grandis-E. coli shuttle vector pRADN8 Using the shuttle vector pRADN1 derived from the Deinococcus radiodurans-E. coli shuttle vector pI3 (see Ohba et al., Gene, 363:133-141, 2005) as a template, a 3,164 bp fragment containing a replicon (pUE10 rep) derived from the Deinococcus radiodurans Sark strain plasmid pUE10 was amplified by PCR and then digested with the restriction enzymes XhoI and EcoRV. In addition, the plasmid pKatCAT5 (see Non-Patent Document 13), which can express the chloramphenicol resistance gene (cat) derived from pcDNA3.1CAT using the catalase gene promoter (katA-p) of Deinococcus radiodurans, was digested with XhoI and EcoRV. These fragments were ligated to construct the plasmid pRADN7.

[0095] Next, a 1,997 bp fragment containing a replicon (pSC101 ori rep) was PCR-amplified using the E. coli vector pGBM5 as a template and then digested with restriction enzymes XhoI and HindIII. Plasmid pRADN7 was also digested with XhoI and HindIII to obtain a 4,063 bp DNA fragment. These DNA fragments were ligated to construct plasmid pRADN8. A map of shuttle vector pRADN8 is shown in Figure 5. In Figure 5, pUE10 rep represents the replicon derived from Deinococcus radiodurans Sark strain plasmid pUE10, pSC101 ori rep represents the replicon derived from E. coli vector pSC101, katA-p represents the catalase gene promoter of Deinococcus radiodurans, and cat represents the chloramphenicol resistance gene derived from E. coli vector pcDNA3.1CAT.

[0096] The primers used for PCR amplification are as follows (SEQ ID NOs: 25 to 28). The primers were designed with reference to the following DNA databases: - the base sequence of vector pI3 (https: / / www.ncbi.nlm.nih.gov / nuccore / AF206717), and - the base sequence of plasmid pSC101 (https: / / www.ncbi.nlm.nih.gov / nuccore / NC_002056.1). The underlined sequences indicate restriction enzyme digestion sites.

[0097] Forward primer of the replicon derived from Deinococcus radiodurans Sark strain plasmid pUE10 (pRADN1-Xho-F2: SEQ ID NO: 25) ATGCCTCGAGCCAGTTCTCGCGTGTCAGCCGA

[0098] Reverse primer of the replicon derived from Deinococcus radiodurans Sark strain plasmid pUE10 (pRADN1-EcoRV-R: SEQ ID NO: 26) GCATGATATCCGATTCGACCTGCAGGCATGC

[0099] Forward primer of the replicon derived from E. coli vector pSC101 (pGBM5-HindIII-F: SEQ ID NO: 27) GCATAAGCTTGACTCTAGAGGATCCCCGGG

[0100] Reverse primer of the replicon derived from E. coli vector pSC101 (pGBM5-XhoI-R: SEQ ID NO: 28) ATGCCTCGAGATGTAACGGTGAACAGTTGTTCTAC

[0101] Example 5: Construction of Deinococcus grandis-Escherichia coli shuttle vector pZT29H Shuttle vector pZT29H was constructed by ligating a 2,109 bp DNA fragment obtained by treating shuttle vector pZT29, which is one of the pZT15-based shuttle vectors described in Patent Document 1 and is described in Non-Patent Document 13, with the restriction enzyme KpnI, and a 2,492 bp DNA fragment obtained by treating hygromycin resistance gene delivery plasmid pKatHPH, described in Murakami et al., PLOS ONE, 16: e0258553, 2021, with KpnI. A map of shuttle vector pZT29H is shown in Figure 6. In Figure 6, pUE30 rep represents the replicon derived from the plasmid pUE30 of Deinococcus radiopugnans ATCC19172, pUC19 ori represents the replicon derived from the E. coli vector pUC19, katA-p represents the catalase gene promoter of Deinococcus radiodurans, and hyg represents the hygromycin resistance gene derived from the E. coli vector pDR2.

[0102] Example 6: Production of Deinococcus grandis transformants using Deinococcus grandis-E. coli shuttle vectors The shuttle vector pGRC5 constructed in Example 3, the shuttle vector pRADN8 constructed in Example 4, and the shuttle vector pZT29H constructed in Example 5 were introduced into the Deinococcus grandis TY3 strain prepared in Example 2 to obtain transformants. Streptomycin was used as a selection marker when obtaining transformants into which pGRC5 had been introduced, chloramphenicol was used when obtaining transformants into which pRADN8 had been introduced, and hygromycin was used when obtaining transformants into which pZT29H had been introduced. Next, plasmids were extracted from the Deinococcus grandis transformants using the same procedures as in Example 1, and whether the plasmids were retained in the cells was confirmed by agarose gel electrophoresis.

[0103] The results are shown in Figure 7. In this figure, lane 1 represents the plasmid pDERG-3 (8,055 bp) extracted from the Deinococcus grandis TY1 strain, and lane 2 represents the extract from the Deinococcus grandis TY3 strain. Lane 3 represents a transformant into which pGRC5 (3,908 bp) was introduced, lane 4 represents a transformant into which pZT29H (4,601 bp) was introduced, lane 5 represents a transformant into which pRADN8 (6,046 bp) was introduced, lane 6 represents a transformant simultaneously containing two types of plasmids, pGRC5 and pZT29H, lane 7 represents a transformant simultaneously containing two types of plasmids, pZT29H and pRADN8, lane 8 represents a transformant simultaneously containing two types of plasmids, pRADN8 and pGRC5, lane 9 represents a transformant simultaneously containing three types of plasmids, pGRC5, pZT29H, and pRADN8, and lane M represents a commercially available supercoiled DNA size marker. The arrow indicates genomic DNA present in the plasmid extract.

[0104] In lanes 3, 6, and 9, a band at 3,908 bp derived from pGRC5 was observed, indicating that pGRC5 exists only as a monomer in the Deinococcus grandis TY3 strain. In lane 4, a band at 4,601 bp derived from the pZT29H monomer and a band at 9,202 bp derived from the pZT29H dimer were observed. In lane 5, a band at 6,046 bp derived from the pRAND8 monomer and a band at 12,092 bp derived from the pRAND8 dimer were observed. Comparing lanes 3, 4, 6, and 9, there was no significant difference in the abundance of plasmid pGRC5 between transformants containing only plasmid pGRC5 and those containing other plasmids, such as pGRC5 and pZT29H. Similarly, comparing lanes 4, 6, 7, and 9, there was no significant difference in the amount of plasmid pZT29H present between transformants containing plasmid pZT29H alone and those containing other plasmids pGRC5 and pRAND8. On the other hand, comparing lanes 5, 7, 8, and 9, the amount of plasmid pRAND8 present was greater in the form of a dimer than in the monomer in transformants containing other plasmids pGRC5 and pZT29H than in transformants containing plasmid pRAND8 alone. In lane 8, multiple bands were observed at locations with lower mobility than the genomic DNA electrophoresis position. This is thought to be due to the formation of multimers of pRADN8 (dimers or higher) in transformants containing both plasmids pRADN8 and pGRC5. These results indicate that plasmids pGRC5, pZT29H, and pRAND8 can coexist in the Deinococcus grandis TY3 strain.

[0105] Example 7: Construction of a Plasmid Expressing the Lobster Luciferase Gene The shuttle plasmid pZT90 described in Non-Patent Document 13 is an expression vector containing the Deinococcus radiodurans groES promoter sequence. Using pZT90 as a template, a 152-bp fragment containing the Deinococcus radiodurans groES promoter region was PCR-amplified and then treated with the restriction enzymes KpnI and NcoI. This DNA fragment was inserted into the KpnI-NcoI site of the plasmid pRNKAAD constructed in Example 2 to construct pGNKAAD.

[0106] Using the plasmid pGNKAAD as a template, the Deinococcus radiodurans groES promoter and the shrimp lobster luciferase gene were PCR-amplified using the primers of SEQ ID NOs: 31 and 32 to obtain a 669-bp DNA fragment. The resulting DNA fragment was treated with the restriction enzymes BamHI and PstI and inserted into the restriction enzyme BamHI-PstI site of the shuttle vector pGRC5 constructed in Example 3, thereby constructing the luciferase gene expression plasmid pGRC5GN.

[0107] Using the plasmid pGNKAAD as a template, the Deinococcus radiodurans groES promoter and the shrimp lobster luciferase gene were PCR-amplified using the primers of SEQ ID NOs: 33 and 34 to obtain a 667-bp DNA fragment. The fragment was treated with the restriction enzymes SalI and HindIII and inserted into the restriction enzyme SalI-HindIII site of the shuttle vector pRADN8 constructed in Example 4 to construct the luciferase gene expression plasmid pRADN8GN.

[0108] Using the plasmid pGNKAAD as a template, the Deinococcus radiodurans groES promoter and the shrimp lobster luciferase gene were PCR-amplified using primers of SEQ ID NOs: 31 and 35 to obtain a 669-bp DNA fragment. The resulting DNA fragment was treated with restriction enzymes BamHI and XbaI and inserted into the restriction enzyme BamHI-XbaI site of the shuttle vector pZT29H constructed in Example 5 to construct the luciferase gene expression plasmid pZT29HGN.

[0109] The primers used for PCR amplification are as follows (SEQ ID NOs: 29 to 35). The primers were designed with reference to: the genomic sequence of Deinococcus radiodurans (https: / / www.ncbi.nlm.nih.gov / nuccore / NZ_CP038663.1), and the nucleotide sequence of pNL1.1[Nluc] (https: / / www.ncbi.nlm.nih.gov / nuccore / JQ437370.1). Restriction enzyme digestion sites are underlined.

[0110] Forward primer for the groES promoter region of plasmid pZT90 (groEp-Kpn-F: SEQ ID NO: 29) CGACGGTACCGATTGTCAGCTTCGGTCA

[0111] Reverse primer for the groES promoter region of plasmid pZT90 (groEp-Nco-R: SEQ ID NO: 30) CTTACCATGGGGGGTCCTCCCTGTGAGTGAGATG

[0112] Forward primer (GN-BamF: SEQ ID NO: 31) for ligating the Deinococcus radiodurans groES promoter and the shrimp lobster luciferase gene into the plasmid pGRC5 or pZT29H: AGCTGGATCCATTGTCAGCTTCGGTCAGTTGACAT

[0113] Reverse primer (GN-PstR: SEQ ID NO: 32) for ligating the Deinococcus radiodurans groES promoter and the shrimp luciferase gene into the plasmid pGRC5: CTAGCTGCAGTTACGCCAGAATGCGTTCGCA

[0114] Forward primer (GN-SalF: SEQ ID NO: 33) for linking the Deinococcus radiodurans groES promoter and the shrimp luciferase gene to the plasmid pRADN8: AGCTGTCGACATTGTCAGCTTCGGTCAGTTGACAT

[0115] Reverse primer (GN-HinR: SEQ ID NO: 34) for linking the Deinococcus radiodurans groES promoter and the shrimp luciferase gene to the plasmid pRADN8: CTAGAAGCTTACGCCAGAATGCGTTCGCA

[0116] Reverse primer (GN-XbaR: SEQ ID NO: 35) for ligating the Deinococcus radiodurans groES promoter and the shrimp luciferase gene into the plasmid pZT29H: CTAGTCTAGATTACGCCAGAATGCGTTCGCA

[0117] Example 8: Measurement of relative plasmid copy number The Ophiopogon luciferase gene expression plasmids pGRC5GN, pZT29HGN, and pRADN8GN constructed in Example 7 were introduced into Deinococcus grandis TY3 strain in the same manner as in Example 6 to obtain transformants. Plasmids were then extracted from the Deinococcus grandis transformants, and the size and state of the plasmids were confirmed by agarose gel electrophoresis. The results are shown in Figure 8. In Figure 8, lane M represents a commercially available supercoiled DNA size marker, lane 1 represents a transformant introduced with pGRC5GN (4,545 bp), lane 2 represents a transformant introduced with pZT29HGN (5,250 bp), and lane 3 represents a transformant introduced with pRADN8GN (6,683 bp). The arrows indicate genomic DNA present in the plasmid extract.

[0118] In lane 1, a band at 4,545 bp derived from pGRC5GN was observed, indicating that, similar to the results for pGRC5 shown in Example 6, the plasmid carrying the pDEGR-3 replicon exists only as a monomer in the Deinococcus grandis TY3 strain. In lane 2, bands at 5,250 bp derived from the pZT29HGN monomer and at 10,500 bp derived from the pZT29H dimer were observed. In lane 3, a band at 6,683 bp derived from the pRADN8GN monomer was observed, as well as a larger band indicating a multimeric structure of the plasmid.

[0119] To compare the expression levels of the P. truncatula luciferase gene contained in the three types of transformants into which the expression plasmids were introduced, the luciferase activity of the transformants (relative luminescence intensity / absorbance at 600 nm of the transformant culture solution) was measured using the Nano-Glo Luciferase Assay System (Promega). The luciferase activity of the transformant into which pGRC5GN was introduced was 8,886 ± 152, that of the transformant into which pZT29HGN was introduced was 12,706 ± 86, and that of the transformant into which pRADN8GN was introduced was 2,792 ± 106. These values ​​were considered to be proportional to the fluorescence intensity of the expression plasmid bands shown in Figure 8. These results demonstrated gene expression in the Deinococcus grandis TY3 strain from three types of expression plasmids containing the shrimp luciferase gene.

[0120] The present invention can be used in the environmental industry, such as bioremediation, etc. The present invention can also be used in the fields of cosmetics and health food manufacturing.

[0121] Deinococcus grandis TY3 strain (Deinococcus grandis TY3) was dated April 12, 2023, at the National Institute of Technology and Evaluation's Patent Microorganism Depositary (NPMD), an independent administrative institution with an address at Room 122, Kazusa Kamatari 2-5-8, Kisarazu City, Chiba Prefecture, Japan, postal code 292-0818. An international deposit has been made under the Budapest Treaty under the accession number NITE BP-03880.

Claims

1. A method for transforming Deinococcus grandis, comprising: (1) removing endogenous plasmid pDEGR-3 or endogenous plasmid pDEGR-3 and 91,291 bp endogenous plasmid pDEGR-PL from Deinococcus grandis to obtain a genetically modified microbial host cell; (2) constructing the following shuttle vector plasmids: a. a shuttle vector plasmid containing the replication origin of pDEGR-3 removed in (1) above and a replication origin of a plasmid derived from E. coli; b. a shuttle vector plasmid containing the replication origin of a plasmid derived from Deinococcus radiodurans Sark strain and a replication origin of a plasmid derived from E. coli; or c. the shuttle vector plasmid of a above and the shuttle vector plasmid of b above, wherein the two shuttle vector plasmids contain replication origins of plasmids derived from E. coli different from each other; (3) constructing the following expression plasmids: a'. The method includes: (a) an expression plasmid in which one or more target genes for expression in a host cell are inserted into the cloning site of the shuttle vector plasmid constructed in (a) above; (b') an expression plasmid in which one or more target genes for expression in a host cell are inserted into the cloning site of the shuttle vector plasmid constructed in (b) above; or (c') an expression plasmid in which one or more target genes for expression in a host cell are inserted into the cloning site of each shuttle vector plasmid constructed in (c) above, with the proviso that the target genes inserted into each shuttle vector plasmid are different from each other; (4) introducing the expression plasmid constructed in (3) above into E. coli and amplifying it; and (5) transforming the host cell of (1) above with the expression plasmid amplified in (4) above.

2. The method according to claim 1, wherein the replication origin region of pDEGR-3 contained in the shuttle vector plasmid of a corresponds to pDEGR-3 rep, which is a replicon derived from pDEGR-3.

3. The method according to claim 1, wherein the replication origin region of a plasmid derived from the Deinococcus radiodurans Sark strain contained in the shuttle vector plasmid of said b corresponds to pUE10 rep, which is a replicon derived from the Deinococcus radiodurans Sark strain plasmid pUE10.

4. The method of claim 1, wherein the shuttle vector plasmid of (2) further contains an antibiotic resistance gene as a screening marker.

5. The method according to claim 1, further comprising: (3') constructing an expression plasmid in which one or more target genes to be expressed in a host cell are inserted into a cloning site of a shuttle vector plasmid selected from the plasmids of the Deinococcus / E. coli shuttle vector pZT15 series, wherein the target genes are different from any of the target genes of a' to c' and the shuttle vector plasmid contains a replication origin of an E. coli-derived plasmid different from the replication origin of an E. coli-derived plasmid contained in a' to c'; (4') introducing the expression plasmid constructed in (3') above into E. coli to amplify it; and (5') transforming the host cell of (1) above with the expression plasmid amplified in (4') above.

6. The method of claim 5, wherein the (3') shuttle vector plasmid further comprises an antibiotic resistance gene as a screening marker.

7. A shuttle vector plasmid comprising the pDEGR-3 rep region, which is a replicon derived from the endogenous plasmid pDEGR-3 of Deinococcus grandis, the p15A ori region, which is a replicon derived from the E. coli vector pACYC184, and an antibiotic resistance gene as a screening marker.

8. The shuttle vector plasmid of claim 7, wherein the antibiotic resistance gene is the aad gene, which is a streptomycin resistance gene from the E. coli vector pGBM5.

9. A shuttle vector plasmid comprising the pUE10 rep region, which is a replicon derived from the Deinococcus radiodurans Sark strain plasmid pUE10, the pSC101 ori rep region, which is a replicon derived from the E. coli vector pSC101, and a second antibiotic resistance gene as a screening marker.

10. The shuttle vector plasmid of claim 9, wherein the second antibiotic resistance gene is the cat gene, a chloramphenicol resistance gene from the E. coli vector pcDNA3.1CAT.

11. An expression plasmid comprising one or more target genes inserted into the cloning site of the shuttle vector plasmid according to claim 7 or 8 for expression in a host cell.

12. An expression plasmid comprising one or more target genes inserted into the cloning site of the shuttle vector plasmid according to claim 9 or 10 for expression in a host cell.

13. A transformant, in which the expression plasmid according to claim 11 is introduced into the genetically modified microbial host cell according to claim 1.

14. A transformant, in which the expression plasmid according to claim 12 is introduced into the genetically modified microbial host cell according to claim 1.

15. A transformant in which the expression plasmid according to claim 11 and the expression plasmid according to claim 12, each of which has a different gene of interest inserted therein, are introduced into a recombinant microbial host cell according to claim 1, thereby enabling expression of different genes on the two types of plasmids.

16. A transformant according to claim 13, further comprising a second expression plasmid, wherein the second expression plasmid contains one or more second target genes inserted into the cloning site of a shuttle vector plasmid selected from the Deinococcus / Escherichia coli shuttle vector pZT15 series plasmids, and the replication origin region of an Escherichia coli-derived plasmid contained in the shuttle vector plasmid is not the p15A ori region, thereby enabling expression of different genes on two types of plasmids.

17. A transformant according to claim 14, further comprising a second expression plasmid, wherein the second expression plasmid contains one or more second genes of interest inserted into a cloning site of a shuttle vector plasmid selected from the Deinococcus / E. coli shuttle vector pZT15 series of plasmids, and the replication origin region of an E. coli-derived plasmid contained in the shuttle vector plasmid is not the pSC101 ori rep region, thereby enabling expression of different genes on two types of plasmids.

18. A transformant according to claim 15, further comprising a third expression plasmid, wherein the third expression plasmid contains one or more third target genes inserted into a cloning site of a shuttle vector plasmid selected from the Deinococcus / Escherichia coli shuttle vector pZT15 series plasmids, and the replication origin region of an Escherichia coli-derived plasmid contained in the shuttle vector plasmid is neither the p15A ori region nor the pSC101 ori rep region, thereby enabling expression of three different genes on the plasmids.

Citation Information

Patent Citations

  • Method for preparing radio-resistant bacterium having luciferase activity

    CN101113426A

  • Radioresistant bacterium / Colon bacillus shuttle vector

    JP2003245078A